7th December 2011 - New research


Pharmacological Research [2011] Nov 23 [Epub ahead of print] (Mokhles MM, Trifirņ G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, Mazzaglia G, Herings R, de Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, van Camp G, Zanettini R, Sturkenboom MC.)  Complete abstract

The use of pramipexole by people with Parkinson's Disease has been found to increase the risk of heart failure. Pramipexole is a dopamine agonist that is also known as Mirapex, Mirapexin, or Sifrol. For more information go to Mirapex. Pramipexole increased the risk of heart failure in people with Parkinson's Disease by 61%. In the first three months of therapy, the risk of using pramipexole was far greater, as it trebled the risk of heart failure. The risk also increased with age, as the risk of heart failure in those people with Parkinson's Disease over 80 years old taking pramipexole was also trebled. When other dopamine agonists were assessed the researchers found no risk of an increase in heart failure in people with Parkinson's Disease.
For more current news go to Parkinson's Disease News.

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

















Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports



©2006-2011  Viartis
2015-09-06 12:51:59
[email protected]